Description
Pomalidomide is sold by Celgene Inc., in the USA, under the brand name Pomalyst. Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalidomide is available under the name of Pomalid and is available in 3 different powers which are as follows Pomalid 1MG, 2MG, and 4MG.
